Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
Semax
In plain language
Semax is a Russian nootropic — modified ACTH 4-7 fragment. Registered for ischemic stroke. Elevates in hippocampus.
For researchers
Semax is a synthetic 7-amino acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro), representing modified fragment 4-7 of ACTH with added C-terminal stabilizing sequence. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Classified as nootropic with neuroprotective activity. In Russia registered by the Ministry of Health for treatment of ischemic stroke (since 2002) and optic neuropathies. The mechanism involves elevation of (brain-derived neurotrophic factor) in hippocampus, modulation of melanocortin-4 receptor and influence on serotonin/dopamine neurotransmitter systems. Published studies by Levitskaya and colleagues (Institute of Molecular Genetics, Moscow) document potential in cognitive disorders, ADHD and recovery after brain injury. Administered intranasally; half-life ~30 minutes. Storage: -20°C lyophilized.
Scientific literature
Other peptides
Information about Semax is based on published scientific research and is intended for research purposes. Not medical advice.
Products related to this peptide are for in vitro laboratory research only. Not approved for human consumption.